Transplant Infections in Developing Countries

Chapter

Abstract

Developing countries located in tropical or subtropical regions have epidemiological characteristics different from developed countries with temperate climates. The former are characterized by the occurrence of endemic infections and diseases that are absent or rare in developed countries, which may not be prepared to diagnose or manage them.

As a consequence of globalization, several factors such as international commerce, tourism, immigration, among others, have acted as important features for the emergence or re-emergence in developed countries, of infectious diseases previously referred as “tropical.”

Many tropical diseases may be transmitted by transplantation and the higher rate of incident infection transmitted by organ donors compared with blood donors emphasizes the need for an international network for biovigilance of organ recipients. Thus, health professionals in the field of transplant infectious diseases need to be prepared to recognize the epidemiological risks and to manage tropical infections in transplant recipients.

Keywords

Tropical diseases Transplantation Developing countries Epidemiological risk 

References

  1. 1.
    Medina-Pestana JO, Duro-Garcia V. Strategies for establishing organ transplant programs in developing countries: the Latin America and Caribbean experience. Artif Organs. 2006;30(7):498–500.PubMedCrossRefGoogle Scholar
  2. 2.
    Associação Brasileira de Transplante de Orgãos. Dimensionamento dos Transplantes no Brasil e em cada estado [Internet]. Registro Brasileiro de Transplantes. 2014. http://www.abto.org.br/abtov03/Upload/file/RBT/2014/rbt2014-lib.pdf
  3. 3.
    WHO. Dengue guidelines for diagnosis, treatment, prevention and control [Internet]. 2009. http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf?ua=1
  4. 4.
    Pandey N, Jain A, Garg RK, Kumar R, Agrawal OP, Lakshmana Rao PV. Serum levels of IL-8, IFNgamma, IL-10, and TGF beta and their gene expression levels in severe and non-severe cases of dengue virus infection. Arch Virol. 2015;160(6):1463–75.PubMedCrossRefGoogle Scholar
  5. 5.
    WHO. Dengue outbreaks [Internet]. 2015. http://www.who.int/csr/don/archive/disease/dengue_fever/en/
  6. 6.
    PAHO—WHO. Number of reported cases of dengue in the Americas, by country: EW 16, 2015 [Internet]. 2015. http://www.paho.org/hq/index.php?option=com_topics&view=article&id=1&Itemid=40734
  7. 7.
    Rigau-Pérez JG, Vorndam AV, Clark GG. The dengue and dengue hemorrhagic fever epidemic in Puerto Rico, 1994-1995. Am J Trop Med Hyg [Internet]. 2001;64(1–2):67–74. http://www.ncbi.nlm.nih.gov/pubmed/11425166
  8. 8.
    Chacko B, John GT, Jacob C. Dengue shock syndrome in a renal transplant recipient. Transplantation. 2004;77(4):635.CrossRefGoogle Scholar
  9. 9.
    Garcia J, Rocha T, Viana C, Girão E, Vasconcelos J, Coelho G, et al. Dengue shock syndrome in a liver transplant recipient. Transplantation. 2006;82(6):850–1.PubMedCrossRefGoogle Scholar
  10. 10.
    Renaud CJ, Manjit K, Pary S. Dengue has a benign presentation in renal transplant patients: a case series. Nephrology (Carlton). 2007;12(3):305–7.CrossRefGoogle Scholar
  11. 11.
    Tan FL, Loh DL, Prabhakaran K, Tambyah PA, Yap HK. Dengue haemorrhagic fever after living donor renal transplantation. Nephrol Dial Transplant. 2005;20(2):447–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Azevedo LS, Carvalho DBM, Matuck T, Alvarenga MF, Morgado L, Magalhães I, et al. Dengue in renal transplant patients: a retrospective analysis. Transplantation. 2007;84(6):792–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Park SB, Ryu SY, Jin KB, Hwang EA, Han SY, Kim HT, et al. Acute colitis associated with dengue fever in a renal transplant recipient. Transplant Proc. 2008;40(7):2431–2.PubMedCrossRefGoogle Scholar
  14. 14.
    Prasad N, Bhadauria D, Sharma RK, Gupta A, Kaul A, Srivastava A. Dengue virus infection in renal allograft recipients: a case series during 2010 outbreak. Transpl Infect Dis [Internet]. 2012;14(2):163–8. http://www.ncbi.nlm.nih.gov/pubmed/22212524
  15. 15.
    Ullah K, Ahmed P, Raza S, Satti T, Nisa Q, Mirza S, et al. Allogeneic stem cell transplantation in hematological disorders: single center experience from Pakistan. Transplant Proc. 2007;39(10):3347–57.PubMedCrossRefGoogle Scholar
  16. 16.
    Machado CM, Martins TC, Colturato I, Leite MS, Simione AJ, De Souza MP, et al. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop Sao Paulo. 2009;51(6):309–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Nasim A, Anis S, Baqi S, Akhtar SF, Baig-Ansari N. Clinical presentation and outcome of dengue viral infection in live-related renal transplant recipients in Karachi, Pakistan. Transpl Infect Dis [Internet]. 2013;15(5):516–25. http://www.scopus.com/inward/record.url?eid=2-s2.0-84884979424&partnerID=tZOtx3y1
  18. 18.
    Saigal S, Choudhary NS, Saraf N, Kataria S, Mohanka R, Soin A. Transmission of dengue virus from a donor to a recipient after living donor liver transplantation. Liver Transpl. 2007;13(3):465–6.Google Scholar
  19. 19.
    Weerakkody R, Palangasinghe D, Dalpatadu KP, Rankothkumbura J, Cassim MR, Karunanayake P. Dengue fever in a liver-transplanted patient: a case report. J Med Case Rep [Internet]. 2014;8(1):378. http://www.jmedicalcasereports.com/content/8/1/378
  20. 20.
    Punzel M, Korukluoğlu G, Caglayik DY, Menemenlioglu D, Bozdag SC, Tekgündüz E, Altuntaş F, Campos Rde M, Burde B, Günther S, Tappe D, Cadar D, Schmidt-Chanasit J. Dengue virus transmission by blood stem cell donor after travel to Sri Lanka; Germany, 2013. Emerg Infect Dis. 2014;20(8):1366-9.Google Scholar
  21. 21.
    Busch MP, Linnen JM, Vinelli E, Sabino EC, Tobler LH, Hyland C, et al. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion. 2008;48(7):1355–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Stramer SL, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion. 2012;52(8):1657–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Dias LL, Amarilla AA, Poloni TR, Covas DT, Aquino VH, Figueiredo LTM. Detection of dengue virus in sera of Brazilian blood donors. Transfusion. 2012;52(8):1667–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Levi JE, Nishiya A, Félix AC, Salles NA, Sampaio LR, Hangai F, et al. Real-time symptomatic case of transfusion-transmitted dengue. Transfusion [Internet]. 2015;55(5):961–4. http://doi.wiley.com/10.1111/trf.12944
  25. 25.
    Qing M, Yang F, Zhang B, Zou G, Robida JM, Yuan Z, et al. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob Agents Chemother. 2009;53(8):3226–35.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Barrett ADT, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209–29.PubMedCrossRefGoogle Scholar
  27. 27.
    Da Costa Vasconcelos PF. Febre amarela. Rev Soc Bras Med Trop. 2003;36(2):275–93.CrossRefGoogle Scholar
  28. 28.
    WHO. Yellow fever [Internet]. 2015 [cited 2015 May 15]. http://www.emro.who.int/health-topics/yellow-fever/index.html
  29. 29.
    Panamerican Health Organization. Small bites big threats—yellow fever [Internet]. Fact Sheet no. 100. 2014. http://www.paho.org/world-health-day-2014/wp-content/uploads/2014/04/Yellow-fever.pdf
  30. 30.
    Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR-17):1–11; quiz CE1–E4.Google Scholar
  31. 31.
    Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34(10):1369–78.PubMedCrossRefGoogle Scholar
  32. 32.
    Wyplosz B, Burdet C, François H, Durrbach A, Duclos-Vallée JC, Mamzer-Bruneel MF, et al. Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation. Am J Transplant. 2013;13(9):2458–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Duchini A, Goss JA, Karpen S, Paul J, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Society. 2003;16(3):357–64.Google Scholar
  34. 34.
    Vasconcelos PFC, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VLRS, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Azevedo LS, Lasmar EP, Contieri FLC, Boin I, Percegona L, Saber LTS, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14(3):237–41.PubMedCrossRefGoogle Scholar
  36. 36.
    Verolet CM, Posfay-Barbe KM. Live virus vaccines in transplantation: friend or foe? Curr Infect Dis Rep [Internet]. 2015;17(4):472. http://link.springer.com/10.1007/s11908-015-0472-y
  37. 37.
    Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect [Internet]. Eur Soc Clin Microbiol Infect Dis; 2012;18(Suppl 5):93–9. http://dx.doi.org/10.1111/j.1469-0691.2012.03971.x
  38. 38.
    Ljungman P. Vaccination after hematopoietic stem cell transplantation. In: Plotkin, Orenstein, Offit, editors. Vaccine. 5th ed. Philadelphia: Saunders Elsevier; 2008. p. 1403–16.Google Scholar
  39. 39.
    Gowda R, Cartwright K, Bremner JAG, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol. 2004;72(4):299–301.PubMedCrossRefGoogle Scholar
  40. 40.
    Reinhardt B, Jaspert R, Niedrig M, Kostner C, L’age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection. J Med Virol. 1998;56(2):159–67.PubMedCrossRefGoogle Scholar
  41. 41.
    Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol. 2006;208(2):199–214.PubMedCrossRefGoogle Scholar
  42. 42.
    WHO. Measles—fact sheet no. 286 [Internet]. 2015. http://www.who.int/mediacentre/factsheets/fs286/en/
  43. 43.
    WHO. Increased transmission and outbreaks of measles, European Region, 2011 [Internet]. Weekly epidemiological record. 2011. p. 559–64. http://www.who.int/wer/2011/wer8649.pdf
  44. 44.
    Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS. Measles—United States, January 4–April 2, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(14):373–6.Google Scholar
  45. 45.
    Machado CM, Gonçalves FB, Pannuti CS, Dulley FL, De Souza VA. Measles in bone marrow transplant recipients during an outbreak in São Paulo, Brazil. Blood. 2002;99(1):83–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Warmington L, Lee BE, Robinson JL. Loss of antibodies to measles and varicella following solid organ transplantation in children. Pediatr Transplant. 2005;9(3):311–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Ljungman P, Lewensohn-Fuchs I, Hammarström V, Aschan J, Brandt L, Bolme P, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84(2):657–63.PubMedGoogle Scholar
  48. 48.
    Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35(8):787–91.PubMedCrossRefGoogle Scholar
  49. 49.
    Yoo J-H, Lee D-G, Choi SM, Choi J-H, Park Y-H, Kim Y-J, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant. 2004;34(6):497–504.PubMedCrossRefGoogle Scholar
  50. 50.
    Agamanolis DP, Tan JS, Parker DL. Immunosuppressive measles encephalitis in a patient with a renal transplant. Arch Neurol. 1979;36(11):686–90.Google Scholar
  51. 51.
    Kalman S, Bakkaloglu SA, Ozkaya O, Buyan N, Söylemezoglu O. Measles: a rare communicable disease in a child with renal transplantation. Pediatr Transplant. 2002;6(5):432–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Klapper PE, Cleator G, Clarcke M, Postlethwaite R. Measles immunisation. Arch Dis Child. 1991;66(3):369.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Turner A, Jeyaratnam D, Haworth F, Sinha MD, Hughes E, Cohen B, et al. Measles-associated encephalopathy in children with renal transplants. Am J Transplant. 2006;6(6):1459–65.PubMedCrossRefGoogle Scholar
  54. 54.
    Sternfeld T, Spöri-Byrtus V, Riediger C, Langer R, Friess H, Schmid RM, et al. Acute measles infection triggering an episode of liver transplant rejection. Int J Infect Dis. 2010;14(6):2009–11.CrossRefGoogle Scholar
  55. 55.
    Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis. 2004;189 Suppl 1:S27–35.Google Scholar
  56. 56.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.PubMedCrossRefGoogle Scholar
  57. 57.
    Funaki T, Shoji K, Miyata I, Sakamoto S, Kasahara M, Yoshii H, et al. Serostatus following live attenuated vaccination administered before pediatric liver transplantation. Liver Transpl [Internet]. 2015;21(6):774–83. http://doi.wiley.com/10.1002/lt.24104
  58. 58.
    Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10(1):78–82.PubMedCrossRefGoogle Scholar
  59. 59.
    Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine [Internet]. 2008;26(52):6859–63. http://dx.doi.org/10.1016/j.vaccine.2014.11.052.CrossRefGoogle Scholar
  60. 60.
    Shinjoh M, Hoshino K, Takahashi T, Nakayama T. Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2015;33:701–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Luthy KE, Tiedeman ME, Beckstrand RL, Mills DA. Safety of live-virus vaccines for children with immune deficiency. J Am Acad Nurse Pract. 2006;18(10):494–503.PubMedCrossRefGoogle Scholar
  62. 62.
    Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, et al. Efficacy and safety of immunization for pre- and post- liver transplant children. Transplantation. 2002;74(4):543–50.PubMedCrossRefGoogle Scholar
  63. 63.
    Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123(1):87–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Kawano Y, Suzuki M, Kawada J, Kimura H, Kamei H, Ohnishi Y, et al. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine [Internet]. 2015;33(12):1440–5. http://linkinghub.elsevier.com/retrieve/pii/S0264410X15001322.CrossRefGoogle Scholar
  65. 65.
    Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002;2(6):327–43.PubMedCrossRefGoogle Scholar
  66. 66.
    Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis [Internet]. 2015;9(4):e0003709. http://dx.plos.org/10.1371/journal.pntd.0003709
  67. 67.
    Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    De Serres G, Dallaire F, Côte M, Skowronski DM. Bat rabies in the United States and Canada from 1950 through 2007: human cases with and without bat contact. Clin Infect Dis. 2008;46(9):1329–37.PubMedCrossRefGoogle Scholar
  69. 69.
    Maier T, Schwarting A, Mauer D, Ross RS, Martens A, Kliem V, et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis. 2010;50(8):1112–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med [Internet]. 2005;352(11):1103–11. http://www.ncbi.nlm.nih.gov/pubmed/15784663
  71. 71.
    Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, et al. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008;57(RR-3):1–28.Google Scholar
  72. 72.
    Vora NM. Raccoon rabies virus variant transmission through solid organ transplantation. JAMA [Internet]. 2013;310(4):398. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.7986
  73. 73.
    WHO. Global tuberculosis report 2014 (WHO/HTM/TB/2014.08). 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf
  74. 74.
    Rose DN. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med. 2000;160(10):1513–21.PubMedCrossRefGoogle Scholar
  75. 75.
    WHO. Guidelines on the management of latent tuberculosis infection [Internet]. 2015. http://www.who.int/tb/publications/ltbi_document_page/en/
  76. 76.
    Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12(9):2288–300.PubMedCrossRefGoogle Scholar
  77. 77.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27(5):1266–77.PubMedCrossRefGoogle Scholar
  78. 78.
    Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40(4):581–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM on behalf of the ESG of, (ESGICH) I in CH. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect 2014;20 (Suppl 7) 89–101.Google Scholar
  80. 80.
    Sundberg R, Shapiro R, Darras F, Jensen C, Scantlebury V, Jordan M, McCauley J, Kusne S, Edmond MB, Ho M, Medvick J, Pascoulle W, Hakala T, Simmons RL, Starzl TE. A tuberculosis outbreak in a renal transplant program. Transpl Proc. 2012;29(6):997–1003.Google Scholar
  81. 81.
    Rizvi SA, Naqvi SA, Hussain Z, Hashmi A, Akhtar F, Hussain M, et al. Renal transplantation in developing countries. Kidney Int Suppl [Internet]. 2003;63(83):S96–100. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037245509&partnerID=40&md5=d9053cd92132242fd1ee4e3863ff405f.CrossRefGoogle Scholar
  82. 82.
    Köseoğlu F, Emiroğlu R, Karakayali H, Bilgin N, Haberal M. Prevalence of mycobacterial infection in solid organ transplant recipients. Transplant Proc. 2001;33(1–2):1782–4.PubMedCrossRefGoogle Scholar
  83. 83.
    Bodro M, Sabé N, Santín M, Cruzado JM, Lladó L, González-Costello J, et al. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc [Internet]. 2012;44(9):2686–9. http://dx.doi.org/10.1016/j.transproceed.2012.09.060
  84. 84.
    Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009;48(12):1657–65.PubMedCrossRefGoogle Scholar
  85. 85.
    Morales P, Briones A, Torres JJ, Solé A, Pérez D, Pastor A. Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain. Transplant Proc. 2005;37(9):4050–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Bravo C, Roldán J, Roman A, Degracia J, Majo J, Guerra J, et al. Tuberculosis in lung transplant recipients. Transplantation. 2005;79(1):59–64.PubMedCrossRefGoogle Scholar
  87. 87.
    Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med Rev. 2008;149(3):177-84.Google Scholar
  88. 88.
    Souza M, Perilio L, Santos A, Mamana A, Vilas Boas L, Costa C, et al. Interferon gamma release assay versus tuberculin skin test in the diagnosis of latent tuberculosis infection in hematopoietic stem cell transplant recipients. In: Ruiz MA, Falcão RP, Bordin JO, editors. Rev Bras Hematol Hemoter [Internet]. RS Press Editora; 2012. p. 205. http://www.sbtmo.org.br/userfiles/fck/file/SUPLEMENTO_SBTMO__2012.pdf
  89. 89.
    Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40(4):990–1013.PubMedCrossRefGoogle Scholar
  90. 90.
    Holty J-EC, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009;15(8):894–906.PubMedCrossRefGoogle Scholar
  91. 91.
    De Lemos AS, Vieira MA, Halpern M, Quaresma RG, Borchardt AC, Santos MA, et al. Results of implementation of preventive recommendations for tuberculosis after renal transplantation in an endemic area. Am J Transplant. 2013;13(12):3230–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Stucchi RSB, Boin IFSF, Angerami RN, Zanaga L, Ataide EC, Udo EY. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Transplant Proc [Internet]. 2012;44(8):2406–10. http://dx.doi.org/10.1016/j.transproceed.2012.07.035
  93. 93.
    Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation. 2002;74(6):892–5.PubMedCrossRefGoogle Scholar
  94. 94.
    Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation. 2007;83(12):1557–62.PubMedCrossRefGoogle Scholar
  95. 95.
    Souza M, Perilio L, Santos A, Mamana A, Vilas Boas L, Costa C, et al. Interferon gamma release assay versus tuberculin skin test in the diagnosis of latent tuberculosis infection in hematopoietic stem cell transplant recipients. In: Ruiz MA, Falcão RP, Bordin JO, editors. Rev Bras Hematol Hemoter. RS Press Editora; 2012. p. 205.Google Scholar
  96. 96.
    García-Goez JF, Linares L, Benito N, Cervera C, Cofán F, Ricart MJ, et al. Tuberculosis in solid organ transplant recipients at a Tertiary Hospital in the last 20 years in Barcelona. Spain Transplant Proc. 2009;41(6):2268–70.PubMedCrossRefGoogle Scholar
  97. 97.
    Benito N, Sued O, Moreno A, Horcajada JP, González J, Navasa M, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation. 2002;74(10):1381–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Cordonnier C, Martino R, Trabasso P, Held TK, Akan H, Ward MS, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis. 2004;38(9):1229–36.PubMedCrossRefGoogle Scholar
  99. 99.
    Russo RL, Dulley FL, Suganuma L, França IL, Yasuda MAS, Costa SF. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis. 2010;14 Suppl 3.Google Scholar
  100. 100.
    Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect. 2006;62(4):421–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63(9):1278–86.PubMedCrossRefGoogle Scholar
  102. 102.
    John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney Int. 2001;60(3):1148–53.PubMedCrossRefGoogle Scholar
  103. 103.
    Boggild AK, Keystone JS, Kain KC. Leprosy: a primer for Canadian physicians. CMAJ. 2004;170(1):71–8.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Deps PD, Alves BL, Gripp CG, Aragao RL, Guedes B, Filho JB, et al. Contact with armadillos increases the risk of leprosy in Brazil: a case control study. Indian J Dermatol Venereol Leprol. 2008;74(4):338–42.Google Scholar
  105. 105.
    Clark BM, Murray CK, Horvath LL, Deye GA, Rasnake MS, Longfield RN. Case-control Study of armadillo contact and Hansen’ s disease. Am J Trop Med Hyg. 2008;78(6):962–7.PubMedGoogle Scholar
  106. 106.
    Britton WJ, Lockwood DNJ. Leprosy. Lancet. 2004;363(9416):1209–19.PubMedCrossRefGoogle Scholar
  107. 107.
    Alter A, Huong NT, Singh M, Orlova M, Van Thuc N, Katoch K, et al. Human leukocyte antigen class I region single-nucleotide polymorphisms are associated with leprosy susceptibility in Vietnam and India. J Infect Dis. 2011;203(9):1274–81.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Lockwood DNJ, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ. 2005;83(3):230–5.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Smith WC, van Brakel W, Gillis T, Saunderson P, Richardus JH. The missing millions: a threat to the elimination of leprosy. PLoS Negl Trop Dis [Internet]. 2015;9(4):e0003658. http://dx.plos.org/10.1371/journal.pntd.0003658
  110. 110.
    WHO. Global leprosy situation, 2012 [Internet]. Weekly epidemiological record. 2012. http://www.who.int/wer/2012/wer8734.pdf?ua=1
  111. 111.
    Gasink LB, Seymour C, Blumberg EA, Goldberg LR, Fishman NO. An uncommon presentation of an uncommon disease: leprosy in a heart transplant recipient. J Hear Lung Transplant. 2006;25(7):854–6.CrossRefGoogle Scholar
  112. 112.
    Trindade MA, Palermo ML, Pagliari C, Valente N, Naafs B, Massarollo PCB, et al. Leprosy in transplant recipients: report of a case after liver transplantation and review of the literature. Transpl Infect Dis. 2011;13(1):63–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Guditi S, Ram R, Ismal KM, Sahay M, Dakshinamurthy KV, Girish N, et al. Leprosy in a renal transplant recipient: review of the literature. Transpl Infect Dis. 2009;11(6):557–62.PubMedCrossRefGoogle Scholar
  114. 114.
    Ardalan M, Ghaffari A, Ghabili K, Shoja MM. Lepromatous leprosy in a kidney transplant recipient: a case report. Exp Clin Transplant. 2011;9(3):203–6.PubMedGoogle Scholar
  115. 115.
    Dutra FADR, Araújo MG, Farah KDP, Maciel MMMD, Lucas Junior FDM, Araújo SDA, et al. Multibacillary leprosy in a renal recipient patient: a case report. J Bras Nefrol [Internet]. 2015;37(1):131–4. http://www.gnresearch.org/doi/10.5935/0101-2800.20150019.Google Scholar
  116. 116.
    Pieroni F, Stracieri AB, Moraes DA, Paton EJ, Saggioro FP, Barros GM, et al. Six cases of leprosy associated with allogeneic hematopoietic SCT. Bone Marrow Transplant. 2007;40(9):859–63.PubMedCrossRefGoogle Scholar
  117. 117.
    Machado CM, Martins TC, Colturato I, Leite MS, Simione AJ, De Souza MP, et al. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop Sao Paulo. 2009;51(6):309–24.Google Scholar
  118. 118.
    Modi K, Mancini M, Joyce MP. Lepromatous leprosy in a heart transplant recipient. Am J Transplant. 2003;3(12):1600–1603.Google Scholar
  119. 119.
    Date A, John GT, Thomas PP, Jacob CK. Leprosy and renal transplantation. Leprosy Rev. 1998;69(1):40–5.PubMedCrossRefGoogle Scholar
  120. 120.
    Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA. 2007;298(18):2171–81.PubMedCrossRefGoogle Scholar
  121. 121.
    Dias JP, Bastos C, Araújo E, Mascarenhas AV, Netto EM, Grassi F, et al. Acute Chagas disease outbreak associated with oral transmission. Rev Soc Bras Med Trop. 2008;41(3):296–300.PubMedCrossRefGoogle Scholar
  122. 122.
    Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions—a comprehensive review. Mem Inst Oswaldo Cruz [Internet]. 2015;110(3):277-82. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014005040362&lng=en&nrm=iso&tlng=en
  123. 123.
    WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates [Internet]. 2015. http://www.who.int/wer/2015/wer9006.pdf?ua=1
  124. 124.
    Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol. 2006;22(12):583–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Dias JCP, Prata A, Correia D. Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev Soc Bras Med Trop. 2008;41(2):193–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr Opin Infect Dis. 2008;21(5):476–82.PubMedCrossRefGoogle Scholar
  127. 127.
    Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. Curr Opin Infect Dis [Internet]. 2014;27(5):418–24. http://www.ncbi.nlm.nih.gov/pubmed/25023742
  128. 128.
    Pinazo MJ, Miranda B, Rodríguez-Villar C, Altclas J, Serra MB, García-Otero EC, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev [Internet]. 2011;25(3):91–101. http://dx.doi.org/10.1016/j.trre.2010.12.002
  129. 129.
    Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in transplant working group. Am J Transplant. 2011;11(4):672–80.PubMedCrossRefGoogle Scholar
  130. 130.
    Wendel S. Transfusion transmitted Chagas disease: is it really under control? Acta Trop [Internet]. 2010;115(1–2):28–34. http://dx.doi.org/10.1016/j.actatropica.2009.12.006
  131. 131.
    Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev. 2005;18(1):12–29.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Machado CM, Levi JE. Transplant-associated and blood transfusion-associated tropical and parasitic infections. Infect Dis Clin North Am. 2012;26(2):225–41.PubMedCrossRefGoogle Scholar
  133. 133.
    Chocair PR, Sabbaga E, Amato Neto V, Shiroma M, de Goes GM. Kidney transplantation: a new way of transmitting Chagas disease. Rev Inst Med Trop Sao Paulo [Internet]. 1981;23(6):280–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=chocair+and+transplant+1981
  134. 134.
    D’Albuquerque LA, Gonzalez AM, Filho HL, Copstein JL, Larrea FI, Mansero JM. Liver transplantation from deceased donors serologically positive for Chagas disease. Am J Transplant. 2007;7(3):680–4.PubMedCrossRefGoogle Scholar
  135. 135.
    Riarte A. Chagas’ disease in patients with kidney transplants: 7 years of experience, 1989-1996. Clin Infect Dis [Internet]. 1999;29:561–7. http://www.ncbi.nlm.nih.gov/pubmed/10530448
  136. 136.
    Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant. 2013;13(9):2418–25.PubMedCrossRefGoogle Scholar
  137. 137.
    Mccormack L, Quiñõnez E, Goldaracena N, Anders M, Rodríguez V, Orozco Ganem F, et al. Liver transplantation using Chagas-infected donors in uninfected recipients: a single-center experience without prophylactic therapy. Am J Transplant. 2012;12(10):2832–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med [Internet]. 2014;370(20):1899–908. http://www.ncbi.nlm.nih.gov/pubmed/24827034
  139. 139.
    Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Bocchi EA, et al. Risk factors for Chagas’ disease reactivation after heart transplantation. J Hear Lung Transplant. 2008;27(6):597–602.CrossRefGoogle Scholar
  140. 140.
    Altclas JD, Barcan L, Nagel C, Lattes R, Riarte A. Organ transplantation and Chagas disease. JAMA. 2008;299(10):1134; author reply 1134–5.PubMedCrossRefGoogle Scholar
  141. 141.
    Cura CI, Lattes R, Nagel C, Gimenez MJ, Blanes M, Calabuig E, et al. Early molecular diagnosis of acute Chagas disease after transplantation with organs from Trypanosoma cruzi-infected donors. Am J Transplant. 2013;13(12):3253–61.PubMedCrossRefGoogle Scholar
  142. 142.
    Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71(6):1833–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Fiorelli AI, Santos RH, Oliveira JL, Lourenço-Filho DD, Dias RR, Oliveira AS, et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant Proc [Internet]. 2011;43(1):220–4. http://dx.doi.org/10.1016/j.transproceed.2010.12.046
  144. 144.
    Le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol. 1999;37(6):1953–7.PubMedPubMedCentralGoogle Scholar
  145. 145.
    Cruz I, Morales MA, Noguer I, Alvar J. Leishmania in discarded syringes from intravenous drug users HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1124–5.Google Scholar
  146. 146.
    Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.Google Scholar
  147. 147.
    Antinori S, Schifanella L, Corbellino M. Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis. 2012;31(2):109–18.PubMedCrossRefGoogle Scholar
  148. 148.
    Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8(3):191–9.PubMedCrossRefGoogle Scholar
  149. 149.
    Lessa MM, Lessa HA, Castro TWN, Oliveira A, Scherifer A, Machado P, et al. Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol. 2007;73(6):843–7.PubMedCrossRefGoogle Scholar
  150. 150.
    Clemente WT, Rabello A, Faria LC, Peruhype-Magalhães V, Gomes LI, Da Silva TA, et al. High prevalence of asymptomatic leishmania spp. infection among liver transplant recipients and donors from an endemic area of brazil. Am J Transplant. 2014;14(1):96–101.PubMedCrossRefGoogle Scholar
  151. 151.
    De Silva AA, Silva Filho ÁPE, Sesso RDCC, Esmeraldo RDM, De Oliveira CMC, Fernandes PFCBC, et al. Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases. BMC Infect Dis [Internet]. 2015;15(1):1–10. http://www.biomedcentral.com/1471-2334/15/96.CrossRefGoogle Scholar
  152. 152.
    Lachaud L, Dereure J, Chabbert E, Reynes J, Mauboussin JM, Oziol E, et al. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol. 2000;38(1):236–40.PubMedPubMedCentralGoogle Scholar
  153. 153.
    Bouchekoua M, Trabelsi S, Ben Abdallah T, Khaled S. Visceral leishmaniasis after kidney transplantation: report of a new case and a review of the literature. Transplant Rev (Orlando) [Internet]. 2014;28(1):32–5. http://www.ncbi.nlm.nih.gov/pubmed/24321305
  154. 154.
    Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: an increasing threat for travellers. Clin Microbiol Infect [Internet]. 2005;11(5):343–6. http://dx.doi.org/10.1111/j.1469-0691.2004.01046.x.CrossRefGoogle Scholar
  155. 155.
    Clemente WT, Faria LC, Romanelli RMC, Lima SSS, Cortes JRG, Oliveira APP, et al. Visceral leishmaniasis in liver transplant recipients from an endemic area. Transplantation. 2011;91(7):806–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Halkic N, Ksontini R, Scholl B, Blanc C, Kovacsovics T, Meylan P, et al. Recurrent cytomegalovirus disease, visceral leishmaniosis, and Legionella pneumonia after liver transplantation: a case report. Can J Anaesth. 2004;51(1):84–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Clemente W, Vidal E, Girão E, Ramos ASD, Govedic F, Merino E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case–control study. Clin Microbiol Infect [Internet]. 2015;21(1):89–95. http://linkinghub.elsevier.com/retrieve/pii/S1198743X14000081.CrossRefGoogle Scholar
  158. 158.
    Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TPC, et al. Increasing failure of miltefosine in the treatment of Kala-Azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013;56(11):1530–8.PubMedCrossRefGoogle Scholar
  159. 159.
    Simon I, Wissing KM, Del Marmol V, Antinori S, Remmelink M, Nilufer Broeders E, et al. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transpl Infect Dis [Internet]. 2011;13(4):397–406. http://www.ncbi.nlm.nih.gov/pubmed/21281418
  160. 160.
    Aregawi M, Cibulskis R, Fergus C, Lynch M, Patouillard E, Szilagyi ZWR on behalf of the WGMP. World malaria report 2014 [Internet]. 2014. http://www.who.int/malaria/publications/world_malaria_report_2014/wmr-2014-no-profiles.pdf
  161. 161.
    Martín-Dávila P, Fortún J, López-Vélez R, Norman F, De Oca MM, Zamarrón P, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev. 2008;21(1):60–96.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Reesink HW, Panzer S, Wendel S, Levi JE, Ullum H, Ekblom-Kullberg S, et al. The use of malaria antibody tests in the prevention of transfusion- transmitted malaria. Vox Sang. 2010;98(3 PART. 2):468–78.Google Scholar
  163. 163.
    Chiche L, Lesage A, Duhamel C, Salame E, Malet M, Samba D, Segol P, Treilhaud M. Letters To the Editor. Transplantation. 2003;75(1):166–8.PubMedCrossRefGoogle Scholar
  164. 164.
    Fischer L, Sterneck M, Claus M, Costard-Jäckle A, Fleischer B, Herbst H, et al. Transmission of malaria tertiana by multi-organ donation. Clin Transplant. 1999;13(6):491–5.PubMedCrossRefGoogle Scholar
  165. 165.
    Menichetti F, Bindi ML, Tascini C, Urbani L, Biancfiore G, Doria R, Esposito M, Mozzo R, Catalano G, Filipponi F. Fever, mental impairment, acute anemia, and renal failure in patient undergoing orthotopic liver transplantation: posttransplantation malaria. Liver Transpl. 2007;13(3):465–6.Google Scholar
  166. 166.
    O’Donnell J, Goldman JM, Wagner K, Ehinger G, Martin N, Leahy M, et al. Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation. Bone Marrow Transplant. 1998;21(3):313–4.PubMedCrossRefGoogle Scholar
  167. 167.
    Sabé N, González-Costello J, Oriol I, Sánchez-Salado JC, Ortega S, Oliver E, et al. Donor-transmitted malaria after heart transplant managed successfully with artesunate. Transpl Infect Dis [Internet]. 2014;16(6):999–1002. http://doi.wiley.com/10.1111/tid.12299.CrossRefGoogle Scholar
  168. 168.
    Tran VB, Tran VB, Lin KH. Malaria infection after allogeneic bone marrow transplantation in a child with thalassemia. Bone Marrow Transplant. 1997;19(12):1259–60.PubMedCrossRefGoogle Scholar
  169. 169.
    Kitchen AD, Chiodini PL, Tossell J. Detection of malarial DNA in blood donors—evidence of persistent infection. Vox Sang. 2014;107(2):123–31.PubMedCrossRefGoogle Scholar
  170. 170.
    Inoue J, Machado CM, Lima GFMDC, Nascimento Nascimento MDJC, Colturato VR, di Santi SM. The monitoring of hematopoietic stem cell transplant donors and recipients from endemic areas for malaria. Rev Inst Med Trop Sao Paulo. 2010;52(5):281–4.PubMedCrossRefGoogle Scholar
  171. 171.
    Howden BP, Vaddadi G, Manitta J, Grayson ML. Chronic falciparum malaria causing massive splenomegaly 9 years after leaving an endemic area. Med J Aust. 2005;182(4):186–8.PubMedGoogle Scholar
  172. 172.
    Theunissen C, Janssens P, Demulder A, Noubousié D, Van Esbroek D, Van Gompel A, et al. Falciparum malaria in patient 9 years after leaving malaria endemic area. Emerg Infect Dis. 2009;15(1):115–6.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet [Internet]. 2014;383(9918):723–35. http://linkinghub.elsevier.com/retrieve/pii/S0140673613600240.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Virology LaboratoryInstitute of Tropical Medicine—University of São PauloSão PauloBrazil

Personalised recommendations